3-(1-methylpyrazol-4-yl)-6-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazine | 1239441-30-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡嗪类
• 英文名称: 3-(1-methylpyrazol-4-yl)-6-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazine
• CAS: 1239441-30-5
• 化学式: C₁₃H₁₁N₇
• 分子量: 265.277
• InChiKey: VIKWTGFOEQPBJL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  76.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-bromo-6-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazine 、 1-甲基-1H-吡唑-4-硼酸 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 3-(1-methylpyrazol-4-yl)-6-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazine
  参考文献：
  名称：

  Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases

  摘要：

  A range of 3,6-di(hetero)arylimidazo[1,2-a]pyrazine ATP-competitive inhibitors of CHK1 were developed by scaffold hopping from a weakly active screening hit. Efficient synthetic routes for parallel synthesis were developed to prepare analogues with improved potency and ligand efficiency against CHK1. Kinase profiling showed that the imidazo[1,2-a]pyrazines could inhibit other kinases, including CHK2 and ABL, with equivalent or better potency depending on the pendant substitution. These 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines appear to represent a general kinase inhibitor scaffold.

  DOI：

  10.1016/j.bmcl.2010.05.096

文献信息

• Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases
  作者：Thomas P. Matthews、Tatiana McHardy、Suki Klair、Kathy Boxall、Martin Fisher、Michael Cherry、Charlotte E. Allen、Glynn J. Addison、John Ellard、G. Wynne Aherne、Isaac M. Westwood、Rob van Montfort、Michelle D. Garrett、John C. Reader、Ian Collins

  DOI：10.1016/j.bmcl.2010.05.096

  日期：2010.7

  A range of 3,6-di(hetero)arylimidazo[1,2-a]pyrazine ATP-competitive inhibitors of CHK1 were developed by scaffold hopping from a weakly active screening hit. Efficient synthetic routes for parallel synthesis were developed to prepare analogues with improved potency and ligand efficiency against CHK1. Kinase profiling showed that the imidazo[1,2-a]pyrazines could inhibit other kinases, including CHK2 and ABL, with equivalent or better potency depending on the pendant substitution. These 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines appear to represent a general kinase inhibitor scaffold.